BioLineRx Reports First Quarter 2019 Financial Results and Provides Corporate Update

Tuesday, May 14, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

On track for Phase 2 data read-outs in pancreatic cancer and consolidation AML by year-end 2019

BioLineRx Ltd.

APPENDIX TO CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS

(UNAUDITED)

Three months ended

March 31,

2018

2019

in USD thousands

Adjustments required to reflect net cash used in operating activities:

Income and expenses not involving cash flows:

Depreciation and amortization

140

213

Long-term prepaid expenses

1

1

Exchange differences on cash and cash equivalents

(23)

2

Gain on adjustment of warrants to fair value

(465)

(79)

Share-based compensation

916

284

Warrant issuance costs

-

417

Interest and exchange differences on short-term deposits

(182)

(195)

Interest and linkage differences on loans

(1)

154

386

797

Changes in operating asset and liability items:

Decrease (increase) in prepaid expenses and other receivables

(453)

786

Decrease in accounts payable and accruals

(542)

(50)

(995)

736

(609)

1,533

Supplemental information on interest received in cash

167

229

Supplemental information on non-cash transaction:

        Initial establishment of right-of-use assets against lease liabilities

-

1,878



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store